HRMY
Harmony Biosciences Holdings, Inc.
Biotechnology · Healthcare · United States
38.50
close · 2026-08-13
value
96
cheaper than peers96
quality
86
stronger fundamentals86
ranked against
Biotechnology (commercial)
value
quality
101 peerswide variation
Value inputs
| measure | company | vs peers |
| forward P/E | 5.76× | 99 |
| price to sales | 2.33× | 95 |
| price to book | 2.24× | 81 |
| EV to EBITDA | 6.83× | 79 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 34.2% | 90 |
| return on equity | 20.5% | 82 |
| debt to equity | 16.0% | 52 |
| revenue growth | 30.3% | 51 |
4 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | $182.8M |
| employees | 293 |
| first trade | 2020-08-19 |
| next earnings | 2026-08-04 |
| fundamentals updated | 2026-08-07 |